Core Viewpoint - The announcement highlights the registration of the Iberis RDN system in Indonesia, marking a significant step in the commercialization of this unique renal denervation product [1] Group 1: Product Development - The Iberis RDN system, developed by Shanghai Antong Medical Technology Co., Ltd., is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - TRA enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1] Group 2: Strategic Partnerships - Antong has formed a strategic partnership with Borson International Group Ltd. to commercialize the Iberis RDN system across multiple regions, including but not limited to EU countries, the Asia-Pacific region, and Latin America [1] Group 3: Regulatory Milestones - The Iberis RDN system received CE marking in Europe in 2016, indicating its compliance with health, safety, and environmental protection standards [1]
百心安-B(02185)：IBERIS® RDN系统在印度尼西亚洲注册